Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Secukinumab is effective and safe in the long-term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients.
Chicharro P, Llamas-Velasco M, Armesto S, Herrera Acosta E, Vidal D, Vilarrasa E, Rivera-Diaz R, De-la-Cueva P, Martorell-Calatayud A, Ballescà F, Belinchon I, Carretero G, Rodriguez L, Romero-Maté A, Pujol-Montcusí J, Salgado L, Sahuquillo-Torralba A, Coto-Segura P, Baniandrés Rodríguez O, Feltes R, Riera-Monroig J, Dauden E. Chicharro P, et al. Among authors: vilarrasa e. Dermatol Ther. 2022 Dec;35(12):e15929. doi: 10.1111/dth.15929. Epub 2022 Oct 19. Dermatol Ther. 2022. PMID: 36223184
Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting.
Navarro R, Vilarrasa E, Herranz P, Puig L, Bordas X, Carrascosa JM, Taberner R, Ferrán M, García-Bustinduy M, Romero-Maté A, Pedragosa R, García-Diez A, Daudén E. Navarro R, et al. Among authors: vilarrasa e. Br J Dermatol. 2013 Mar;168(3):609-16. doi: 10.1111/bjd.12045. Br J Dermatol. 2013. PMID: 22985451
Redefining the therapeutic objective in psoriatic patients candidates for biological therapy.
Carretero G, Puig L, Carrascosa JM, Ferrándiz L, Ruiz-Villaverde R, de la Cueva P, Belinchon I, Vilarrasa E, Del Rio R, Sánchez-Carazo JL, López-Ferrer A, Peral F, Armesto S, Eiris N, Mitxelena J, Vilar-Alejo J, A Martin M, Soria C; from the Spanish Group of Psoriasis. Carretero G, et al. Among authors: vilarrasa e. J Dermatolog Treat. 2018 Jun;29(4):334-346. doi: 10.1080/09546634.2017.1395794. Epub 2017 Nov 21. J Dermatolog Treat. 2018. PMID: 29099667 Review.
Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain.
Notario J, Deza G, Vilarrasa E, Valentí F, Muñoz C, Mollet J, Rocamora V, Carrascosa JM, Del Alcázar E, Alsina M, Vidal D, Puig L, López-Ferrer A, Riera J, Gallardo F, Ferran M. Notario J, et al. Among authors: vilarrasa e. J Dermatolog Treat. 2019 Aug;30(5):424-429. doi: 10.1080/09546634.2018.1528000. Epub 2018 Dec 3. J Dermatolog Treat. 2019. PMID: 30244618
Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study.
Montes-Torres A, Aparicio G, Rivera R, Vilarrasa E, Marcellán M, Notario J, Soria C, Belinchón I, de la Cueva P, Ferrán M, Carrascosa JM, Gómez FJ, Salgado L, Velasco M, Descalzo MÁ, García-Doval I, Daudén E; ; the BIOBADADERM Study Group and Psoriasis Group of the AEDV. Montes-Torres A, et al. Among authors: vilarrasa e. J Dermatolog Treat. 2019 Aug;30(5):461-465. doi: 10.1080/09546634.2018.1535690. Epub 2018 Nov 28. J Dermatolog Treat. 2019. PMID: 30307344
Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study.
Deza G, Notario J, Lopez-Ferrer A, Vilarrasa E, Ferran M, Del Alcazar E, Carrascosa JM, Corral M, Salleras M, Ribera M, Puig L, Pujol RM, Vidal D, Gallardo F. Deza G, et al. Among authors: vilarrasa e. J Eur Acad Dermatol Venereol. 2019 Mar;33(3):553-559. doi: 10.1111/jdv.15288. Epub 2018 Nov 13. J Eur Acad Dermatol Venereol. 2019. PMID: 30317679
Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study.
Del Alcázar E, Ferran M, López-Ferrer A, Notario J, Vidal D, Riera J, Aparicio G, Gallardo F, Vilarrasa E, Alsina M, Puig L, Ferrándiz C, Carrascosa JM. Del Alcázar E, et al. Among authors: vilarrasa e. J Dermatolog Treat. 2020 May;31(3):222-226. doi: 10.1080/09546634.2019.1597245. Epub 2019 Apr 2. J Dermatolog Treat. 2020. PMID: 30883242
Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group.
Del Alcázar E, Suárez-Pérez JA, Armesto S, Rivera R, Herrera-Acosta E, Herranz P, Martín I, Montesinos E, Hospital M, Vilarrasa E, Ferran M, Ruiz-Villaverde R, Sahuquillo-Torralba A, Ruiz-Genao DP, Pérez-Barrio S, Muñoz C, Llamas M, Valentí F, Mitxelena MJ, López-Ferrer A, Carretero G, Vidal D, Mollet J, Belinchón I, Carrascosa JM. Del Alcázar E, et al. Among authors: vilarrasa e. J Eur Acad Dermatol Venereol. 2020 Dec;34(12):2821-2829. doi: 10.1111/jdv.16439. Epub 2020 Jun 17. J Eur Acad Dermatol Venereol. 2020. PMID: 32271966
The effectiveness and safety of ixekizumab in psoriasis patients under clinical practice conditions: A Spanish multicentre retrospective study.
Rivera R, Velasco M, Vidal D, Carrascosa JM, Daudén E, Vilarrasa E, Notario J, Ruíz-Villaverde R, Yanguas I, García-Latasa FJ, Ferrán M, Lázaro-Simó A, de la Cueva P, Salgado-Boquete L, Belinchón I. Rivera R, et al. Among authors: vilarrasa e. Dermatol Ther. 2020 Nov;33(6):e14066. doi: 10.1111/dth.14066. Epub 2020 Sep 3. Dermatol Ther. 2020. PMID: 32713119
76 results